Hozen MedAsia Inc. is a Philippine registered corporation involved in importation and distribution of a wide range of pharmaceutical, nutraceutical and food supplement finished formulations.

Losarta Potassium
LOSASUN
50mg Film Coated Tablet
Angiotensin-2 Receptor Blocker

INDICATION

Losartan is an angiotensin II receptor antagonist with antihypertensive activity due mainly to selective blockade of AT1 receptors and the consequent reduced pressor effect of angiotensin II. It is used in the management of hypertension, particularly in patients who develop cough with ACE inhibitors and to reduce the risk of stroke in patients with left ventricular hypertrophy, and in the treatment of diabetic nephropathy. It has also been tried in heart failure and in myocardial infarction.

Losartan is given by mouth as the potassium salt. The maximum hypotensive effect is achieved in about 3 to 6 weeks after initiating treatment.

In hypertension the usual dose is 50mg once daily The dose may be increased, if necessary, to 100 mg daily as a single dose or in two divided doses. An initial dose of 25mg once daily should be given to patients with intravascular fluid depletion, and is recommended in the UK in the elderly over 75 years of age. Similar reductions may be appropriate in patients with hepatic or renal impairment.

Children aged 6 years or over with hypertension may be given an initial dose of 700micrograms/kg once daily, with a maximum of 50mg, adjusted according to response; doses higher than 1.4 mg/kg or 100mg daily have not been studied.

In diabetic nephropathy losartan is given in an initial dose of 50mg once daily, increased to 100mg once daily depending on the blood pressure.

DOSAGE AND ADMINISTRATION

Losartan is given by mouth as the potassium salt. The maximum hypotensive effect is achieved in about 3 to 6 weeks after initiating treatment.

In hypertension the usual dose is 50mg once daily. The dose may be increased, if necessary, to 100mg daily as a single dose or in two doses. An initial dose of 25mg once daily should be given to patients with intravascular fluid depletion, and is recommended in the UK in the elderly over 75 years of age. Similar reductions may be appropriate in patients with hepatic or renal impairment.

Children aged 6 years or over with hypertension may be given an initial dose of 700 micrograms/kg once daily, with a maximum of 50mg, adjusted according to response; doses higher than 1.4mg/kg or 100mg daily have not been studied.

In diabetic nephropathy losartan is given in an initial dose of 50mg once daily, increased to 100mg once daily depending on the blood pressure.

DRUG INTERACTIONS

The antihypertensive effects of losartan may be potentiated by drugs or other agents that lower blood pressure. An additive hyperkalaemic effect is possible with potassium supplements, potassium-sparing diuretics or other drugs that can cause hyperkalaemia; losartan and potassium-sparing diuretics should not generally be given together. Losartan and some other angiotensin II receptor antagonists are metabolized by cytochrome P450 isoenymes and interactions may occur with drugs that affect these enymes.

ADVERSE EFFECTS

Adverse effects of losartan have been reported to be usually mild and transient, and include dizziness, headache, and dose-related orthostatic hypotension. Hypotension may occur particularly in patients with volume depletion (for example those who have received high-dose diuretics). Impaired renal function and rarely, rash, urticarial, pruritus, angioedema, and raised liver enzyme values may occur. Hyperkalaemia, myalgia, and arthralgia have been reported with angiotensin II receptor antagonists include respiratory-tract disoreders, back pain, gastrointestinal disturbances, fatigue, and neutropenia.

PRECAUTIONS

Losartan is conta-indicated in pregnancy. It should be used with caution in patients with renal artery stenosis. Losartan is excreted in urine and in bile and reduced doses may therefore be required in patients with renal impairment and should be considered in patients with hepatic impairment. Patients with volume deception (for example those who have received high dose diuretic therapt) may experience hypotension; volume depletion should be corrected before starting therapy, or a low initial dose should be used. Since hyperkalaemia may occur, serum-potassium concentrations should be monitored, especially in the elderly and patients with renal impairment, and the concomitant use of potassium-sparing diuretics should generally be avoided.

STORAGE

Store at a temperature not exceeding 30°C.